The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug


Waltham biotech Morphic Holding Inc. is no longer working with Johnson & Johnson Inc. after the pharma giant elected to terminate a nearly four-year-old collaboration agreement.

Previous Willco Cos. regains control of developable North Bethesda site, following foreclosure
Next CinCor CEO: acquisition by AstraZeneca was more than a year in the making